Epiq Partners, LLC Fate Therapeutics Inc Transaction History

Epiq Partners, LLC

$165 Million
Q3 2024

A detailed history of Epiq Partners, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Epiq Partners, LLC holds 10,366 shares of FATE stock, worth $23,738. This represents 0.02% of its overall portfolio holdings.

Number of Shares

10,366

Holding current value

$23,738

% of portfolio

0.02%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	BUY	$3.12 - $5.57 $32,341 - $57,738	10,366 New	10,366 $36,000
Q4 2023 Jan 11, 2024	BUY	$1.65 - $3.94 $16,617 - $39,679	10,071 New	10,071 $37,000
Q2 2023 Jul 12, 2023	BUY	$4.76 - $6.59 $47,937 - $66,367	10,071 New	10,071 $47,000
Q4 2022 Jan 06, 2023	SELL	$9.86 - $23.83 $12,275 - $29,668	-1,245 Reduced 1.71%	71,521 $0
Q3 2022 Oct 14, 2022	BUY	$21.04 - $36.06 $83,591 - $143,266	3,973 Added 5.78%	72,766 $1.63 Million
Q2 2022 Jul 07, 2022	BUY	$17.78 - $42.39 $195,313 - $465,654	10,985 Added 19.0%	68,793 $1.71 Million
Q1 2022 Apr 27, 2022	BUY	$29.67 - $60.28 $273,112 - $554,877	9,205 Added 18.94%	57,808 $2.24 Million
Q4 2021 Jan 25, 2022	SELL	$47.84 - $64.34 $11,242 - $15,119	-235 Reduced 0.48%	48,603 $2.84 Million
Q3 2021 Oct 19, 2021	SELL	$59.27 - $95.73 $50,201 - $81,083	-847 Reduced 1.7%	48,838 $2.9 Million
Q2 2021 Aug 02, 2021	BUY	$67.25 - $92.52 $197,042 - $271,083	2,930 Added 6.27%	49,685 $4.31 Million
Q1 2021 Apr 16, 2021	BUY	$72.16 - $117.4 $237,189 - $385,893	3,287 Added 7.56%	46,755 $3.86 Million
Q4 2020 Jan 11, 2021	BUY	$38.09 - $100.95 $198,258 - $525,444	5,205 Added 13.6%	43,468 $3.95 Million
Q3 2020 Oct 22, 2020	BUY	$30.41 - $40.5 $1.16 Million - $1.55 Million	38,263 New	38,263 $1.7 Million

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Epiq Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Epiq Partners, LLC with notifications on news.

Account